Cargando…
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
Genomic MET amplification and exon 14 skipping are currently clinically recognized biomarkers for stratifying subsets of non-small cell lung cancer (NSCLC) patients according to the predicted response to c-Met inhibitors (c-Metis), yet the overall clinical benefit of this strategy is quite limited....
Autores principales: | Zhou, Ji, Zhang, Xu-Chao, Xue, Shan, Dai, Mengdi, Wang, Yueliang, Peng, Xia, Chen, Jianjiao, Wang, Xinyi, Shen, Yanyan, Qin, Hui, Chen, Bi, Zheng, Yu, Gao, Xiwen, Xie, Zuoquan, Ding, Jian, Jiang, Handong, Wu, Yi-Long, Geng, Meiyu, Ai, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183461/ https://www.ncbi.nlm.nih.gov/pubmed/37183231 http://dx.doi.org/10.1038/s41392-023-01403-w |
Ejemplares similares
-
Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
por: Wang, Ying, et al.
Publicado: (2016) -
Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020) -
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
por: Miyamoto, M, et al.
Publicado: (2011) -
Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis
por: Zhou, Yi, et al.
Publicado: (2023) -
Clinicopathological and prognostic significance of c-Met overexpression in breast cancer
por: Zhao, Xixi, et al.
Publicado: (2017)